Blue Earth Tx announced the closing of a $76.5M Series A financing, which was led by Soleus Capital and co-led by Sands Capital Management with existing investor Bracco Imaging SpA also participating. The funding will be used to further advance its clinical stage PSMA-targeted radioligand therapies. 

The company's initial focus is on prostate cancer, with plans to expand to additional disease areas within cancer care.